TY  - JOUR
AU  - Pavlović, Marijana
AU  - Kahrović, Emira
AU  - Aranđelović, Sandra
AU  - Radulović, Siniša
AU  - Ilich, Predrag-Peter
AU  - Grgurić-Šipka, Sanja
AU  - Ljubijankić, Nevzeta
AU  - Žilić, Dijana
AU  - Jurec, Jurica
PY  - 2023
UR  - http://cherry.chem.bg.ac.rs/handle/123456789/5901
AB  - Novel ruthenium(III) complexes of general formula Na[
RuCl2(L1−3-N,O)2] where L(
1–3) denote deprotonated Schiff bases
(
HL1-HL3) derived from 5-substituted salicyladehyde and alkylamine (propyl- or butylamine) were prepared and characterized
based on elemental analysis, mass spectra, infrared, electron spin/paramagnetic resonance (ESR/EPR) spectroscopy,
and cyclovoltammetric study. Optimization of five isomers of complex C1 was done by DFT calculation. The interaction
of C1–C3 complexes with DNA (Deoxyribonucleic acid) and BSA (Bovine serum albumin) was investigated by electron
spectroscopy and fluorescence quenching. The cytotoxic activity of C1–C3 was investigated in a panel of four human cancer
cell lines (K562, A549, EA.hy926, MDA-MB-231) and one human non-tumor cell line (MRC-5). Complexes displayed an
apparent cytoselective profile, with IC50
values in the low micromolar range from 1.6 ± 0.3 to 23.0 ± 0.1 μM. Cisplatinresistant
triple-negative breast cancer cells MDA-MB-231 displayed the highest sensitivity to complexes, with Ru(III)
compound containing two chlorides and two deprotonated N-propyl-5-chloro-salicylidenimine (hereinafter C1) as the most
potent (
IC50 = 1.6 μM), and approximately ten times more active than cisplatin (
IC50 = 21.9 μM). MDA-MB-231 cells treated
for 24 h with C1 presented with apoptotic morphology, as seen by acridine orange/ethidium bromide staining, while 48 h of
treatment induced DNA fragmentation, and necrotic changes in cells, as seen by flow cytometry analysis. Drug-accumulation
study by inductively coupled plasma mass spectrometry (ICP-MS) demonstrated markedly higher intracellular accumulation
of C1 compared with cisplatin.
PB  - Springer
T2  - J. Biol. Inorg. Chem.
T1  - Tumor Selective Ru(III) Schiff Bases Complexes with Strong In Vitro Activity Toward Cisplatin-Resistant MDA-MB-231 Breast Cancer Cells
VL  - 28
SP  - 263
EP  - 284
DO  - 10.1007/s00775-023-01989-0
ER  - 

@article{
author = "Pavlović, Marijana and Kahrović, Emira and Aranđelović, Sandra and Radulović, Siniša and Ilich, Predrag-Peter and Grgurić-Šipka, Sanja and Ljubijankić, Nevzeta and Žilić, Dijana and Jurec, Jurica",
year = "2023",
abstract = "Novel ruthenium(III) complexes of general formula Na[
RuCl2(L1−3-N,O)2] where L(
1–3) denote deprotonated Schiff bases
(
HL1-HL3) derived from 5-substituted salicyladehyde and alkylamine (propyl- or butylamine) were prepared and characterized
based on elemental analysis, mass spectra, infrared, electron spin/paramagnetic resonance (ESR/EPR) spectroscopy,
and cyclovoltammetric study. Optimization of five isomers of complex C1 was done by DFT calculation. The interaction
of C1–C3 complexes with DNA (Deoxyribonucleic acid) and BSA (Bovine serum albumin) was investigated by electron
spectroscopy and fluorescence quenching. The cytotoxic activity of C1–C3 was investigated in a panel of four human cancer
cell lines (K562, A549, EA.hy926, MDA-MB-231) and one human non-tumor cell line (MRC-5). Complexes displayed an
apparent cytoselective profile, with IC50
values in the low micromolar range from 1.6 ± 0.3 to 23.0 ± 0.1 μM. Cisplatinresistant
triple-negative breast cancer cells MDA-MB-231 displayed the highest sensitivity to complexes, with Ru(III)
compound containing two chlorides and two deprotonated N-propyl-5-chloro-salicylidenimine (hereinafter C1) as the most
potent (
IC50 = 1.6 μM), and approximately ten times more active than cisplatin (
IC50 = 21.9 μM). MDA-MB-231 cells treated
for 24 h with C1 presented with apoptotic morphology, as seen by acridine orange/ethidium bromide staining, while 48 h of
treatment induced DNA fragmentation, and necrotic changes in cells, as seen by flow cytometry analysis. Drug-accumulation
study by inductively coupled plasma mass spectrometry (ICP-MS) demonstrated markedly higher intracellular accumulation
of C1 compared with cisplatin.",
publisher = "Springer",
journal = "J. Biol. Inorg. Chem.",
title = "Tumor Selective Ru(III) Schiff Bases Complexes with Strong In Vitro Activity Toward Cisplatin-Resistant MDA-MB-231 Breast Cancer Cells",
volume = "28",
pages = "263-284",
doi = "10.1007/s00775-023-01989-0"
}

Pavlović, M., Kahrović, E., Aranđelović, S., Radulović, S., Ilich, P., Grgurić-Šipka, S., Ljubijankić, N., Žilić, D.,& Jurec, J.. (2023). Tumor Selective Ru(III) Schiff Bases Complexes with Strong In Vitro Activity Toward Cisplatin-Resistant MDA-MB-231 Breast Cancer Cells. in J. Biol. Inorg. Chem.
Springer., 28, 263-284.
https://doi.org/10.1007/s00775-023-01989-0

Pavlović M, Kahrović E, Aranđelović S, Radulović S, Ilich P, Grgurić-Šipka S, Ljubijankić N, Žilić D, Jurec J. Tumor Selective Ru(III) Schiff Bases Complexes with Strong In Vitro Activity Toward Cisplatin-Resistant MDA-MB-231 Breast Cancer Cells. in J. Biol. Inorg. Chem.. 2023;28:263-284.
doi:10.1007/s00775-023-01989-0 .

Pavlović, Marijana, Kahrović, Emira, Aranđelović, Sandra, Radulović, Siniša, Ilich, Predrag-Peter, Grgurić-Šipka, Sanja, Ljubijankić, Nevzeta, Žilić, Dijana, Jurec, Jurica, "Tumor Selective Ru(III) Schiff Bases Complexes with Strong In Vitro Activity Toward Cisplatin-Resistant MDA-MB-231 Breast Cancer Cells" in J. Biol. Inorg. Chem., 28 (2023):263-284,
https://doi.org/10.1007/s00775-023-01989-0 . .

TY  - JOUR
AU  - Pavlović, Marijana
AU  - Tadić, Ana
AU  - Gligorijević, Nevenka
AU  - Poljarević, Jelena
AU  - Petrović, Tamara
AU  - Dojčinović, Biljana P.
AU  - Savić, Aleksandar
AU  - Radulović, Siniša
AU  - Grgurić-Šipka, Sanja
AU  - Aranđelović, Sandra
PY  - 2020
UR  - https://cherry.chem.bg.ac.rs/handle/123456789/4048
AB  - Inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1) showed remarkable clinical efficacy in BRCA-mutated tumors. Based on the rational drug design, derivatives of PARP inhibitor 3-aminobenzamide (3-AB), 2-amino-4-methylbenzamide (L1) and 3-amino-N-methylbenzamide (L2), were coordinated to the ruthenium(II) ion, to form potential drugs affecting DNA and inhibiting PARP enzyme. The four conjugated complexes of formula: C1 [(ƞ6-toluene)Ru(L1)Cl]PF6, C2 [(ƞ6-p-cymene)Ru(L1)Cl]PF6, C3 [(ƞ6-toluene)Ru(L2)Cl2] and C4 [(ƞ6-p-cymene)Ru(L2)Cl2], have been synthesized and characterized. Colorimetric 3-(4.5-dimethylthiazol-2-yl)-2.5-diphenyltetrazolium bromide (MTT) assay showed the highest antiproliferative activity of C1 in HCC1937, MDA-MB-231, and MCF-7 breast cancer cells. Efficiency of inhibition of PARP-1 enzymatic activity in vitro decreased in order: C2 > C4 > 3-AB>C1 > C3. ICP-MS study of intracellular accumulation and distribution in BRCA1-mutated HCC1937 revealed that C1-C4 entered cells within 24 h. The complex C1 showed the highest intracellular accumulation, nuclear-targeting properties, and exhibited the highest DNA binding (39.2 ± 0.6 pg of Ru per μg of DNA) that resulted in the cell cycle arrest in the S phase.
PB  - Elsevier
T2  - Journal of Inorganic Biochemistry
T1  - Synthesis, chemical characterization, PARP inhibition, DNA binding and cellular uptake of novel ruthenium(II)-arene complexes bearing benzamide derivatives in human breast cancer cells
VL  - 210
SP  - 111155
DO  - 10.1016/j.jinorgbio.2020.111155
ER  - 

@article{
author = "Pavlović, Marijana and Tadić, Ana and Gligorijević, Nevenka and Poljarević, Jelena and Petrović, Tamara and Dojčinović, Biljana P. and Savić, Aleksandar and Radulović, Siniša and Grgurić-Šipka, Sanja and Aranđelović, Sandra",
year = "2020",
abstract = "Inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1) showed remarkable clinical efficacy in BRCA-mutated tumors. Based on the rational drug design, derivatives of PARP inhibitor 3-aminobenzamide (3-AB), 2-amino-4-methylbenzamide (L1) and 3-amino-N-methylbenzamide (L2), were coordinated to the ruthenium(II) ion, to form potential drugs affecting DNA and inhibiting PARP enzyme. The four conjugated complexes of formula: C1 [(ƞ6-toluene)Ru(L1)Cl]PF6, C2 [(ƞ6-p-cymene)Ru(L1)Cl]PF6, C3 [(ƞ6-toluene)Ru(L2)Cl2] and C4 [(ƞ6-p-cymene)Ru(L2)Cl2], have been synthesized and characterized. Colorimetric 3-(4.5-dimethylthiazol-2-yl)-2.5-diphenyltetrazolium bromide (MTT) assay showed the highest antiproliferative activity of C1 in HCC1937, MDA-MB-231, and MCF-7 breast cancer cells. Efficiency of inhibition of PARP-1 enzymatic activity in vitro decreased in order: C2 > C4 > 3-AB>C1 > C3. ICP-MS study of intracellular accumulation and distribution in BRCA1-mutated HCC1937 revealed that C1-C4 entered cells within 24 h. The complex C1 showed the highest intracellular accumulation, nuclear-targeting properties, and exhibited the highest DNA binding (39.2 ± 0.6 pg of Ru per μg of DNA) that resulted in the cell cycle arrest in the S phase.",
publisher = "Elsevier",
journal = "Journal of Inorganic Biochemistry",
title = "Synthesis, chemical characterization, PARP inhibition, DNA binding and cellular uptake of novel ruthenium(II)-arene complexes bearing benzamide derivatives in human breast cancer cells",
volume = "210",
pages = "111155",
doi = "10.1016/j.jinorgbio.2020.111155"
}

Pavlović, M., Tadić, A., Gligorijević, N., Poljarević, J., Petrović, T., Dojčinović, B. P., Savić, A., Radulović, S., Grgurić-Šipka, S.,& Aranđelović, S.. (2020). Synthesis, chemical characterization, PARP inhibition, DNA binding and cellular uptake of novel ruthenium(II)-arene complexes bearing benzamide derivatives in human breast cancer cells. in Journal of Inorganic Biochemistry
Elsevier., 210, 111155.
https://doi.org/10.1016/j.jinorgbio.2020.111155

Pavlović M, Tadić A, Gligorijević N, Poljarević J, Petrović T, Dojčinović BP, Savić A, Radulović S, Grgurić-Šipka S, Aranđelović S. Synthesis, chemical characterization, PARP inhibition, DNA binding and cellular uptake of novel ruthenium(II)-arene complexes bearing benzamide derivatives in human breast cancer cells. in Journal of Inorganic Biochemistry. 2020;210:111155.
doi:10.1016/j.jinorgbio.2020.111155 .

Pavlović, Marijana, Tadić, Ana, Gligorijević, Nevenka, Poljarević, Jelena, Petrović, Tamara, Dojčinović, Biljana P., Savić, Aleksandar, Radulović, Siniša, Grgurić-Šipka, Sanja, Aranđelović, Sandra, "Synthesis, chemical characterization, PARP inhibition, DNA binding and cellular uptake of novel ruthenium(II)-arene complexes bearing benzamide derivatives in human breast cancer cells" in Journal of Inorganic Biochemistry, 210 (2020):111155,
https://doi.org/10.1016/j.jinorgbio.2020.111155 . .

TY  - DATA
AU  - Pavlović, Marijana
AU  - Tadić, Ana
AU  - Gligorijević, Nevenka
AU  - Poljarević, Jelena
AU  - Petrović, Tamara
AU  - Dojčinović, Biljana P.
AU  - Savić, Aleksandar
AU  - Radulović, Siniša
AU  - Grgurić-Šipka, Sanja
AU  - Aranđelović, Sandra
PY  - 2020
UR  - https://cherry.chem.bg.ac.rs/handle/123456789/4049
PB  - Elsevier
T2  - Journal of Inorganic Biochemistry
T1  - Supplementary data for the article: Pavlović, M.; Tadić, A.; Gligorijević, N.; Poljarević, J.; Petrović, T.; Dojčinović, B.; Savić, A.; Radulović, S.; Grgurić-Šipka, S.; Aranđelović, S. Synthesis, Chemical Characterization, PARP Inhibition, DNA Binding and Cellular Uptake of Novel Ruthenium(II)-Arene Complexes Bearing Benzamide Derivatives in Human Breast Cancer Cells. Journal of Inorganic Biochemistry 2020, 210, 111155. https://doi.org/10.1016/j.jinorgbio.2020.111155
UR  - https://hdl.handle.net/21.15107/rcub_cherry_4049
ER  - 

@misc{
author = "Pavlović, Marijana and Tadić, Ana and Gligorijević, Nevenka and Poljarević, Jelena and Petrović, Tamara and Dojčinović, Biljana P. and Savić, Aleksandar and Radulović, Siniša and Grgurić-Šipka, Sanja and Aranđelović, Sandra",
year = "2020",
publisher = "Elsevier",
journal = "Journal of Inorganic Biochemistry",
title = "Supplementary data for the article: Pavlović, M.; Tadić, A.; Gligorijević, N.; Poljarević, J.; Petrović, T.; Dojčinović, B.; Savić, A.; Radulović, S.; Grgurić-Šipka, S.; Aranđelović, S. Synthesis, Chemical Characterization, PARP Inhibition, DNA Binding and Cellular Uptake of Novel Ruthenium(II)-Arene Complexes Bearing Benzamide Derivatives in Human Breast Cancer Cells. Journal of Inorganic Biochemistry 2020, 210, 111155. https://doi.org/10.1016/j.jinorgbio.2020.111155",
url = "https://hdl.handle.net/21.15107/rcub_cherry_4049"
}

Pavlović, M., Tadić, A., Gligorijević, N., Poljarević, J., Petrović, T., Dojčinović, B. P., Savić, A., Radulović, S., Grgurić-Šipka, S.,& Aranđelović, S.. (2020). Supplementary data for the article: Pavlović, M.; Tadić, A.; Gligorijević, N.; Poljarević, J.; Petrović, T.; Dojčinović, B.; Savić, A.; Radulović, S.; Grgurić-Šipka, S.; Aranđelović, S. Synthesis, Chemical Characterization, PARP Inhibition, DNA Binding and Cellular Uptake of Novel Ruthenium(II)-Arene Complexes Bearing Benzamide Derivatives in Human Breast Cancer Cells. Journal of Inorganic Biochemistry 2020, 210, 111155. https://doi.org/10.1016/j.jinorgbio.2020.111155. in Journal of Inorganic Biochemistry
Elsevier..
https://hdl.handle.net/21.15107/rcub_cherry_4049

Pavlović M, Tadić A, Gligorijević N, Poljarević J, Petrović T, Dojčinović BP, Savić A, Radulović S, Grgurić-Šipka S, Aranđelović S. Supplementary data for the article: Pavlović, M.; Tadić, A.; Gligorijević, N.; Poljarević, J.; Petrović, T.; Dojčinović, B.; Savić, A.; Radulović, S.; Grgurić-Šipka, S.; Aranđelović, S. Synthesis, Chemical Characterization, PARP Inhibition, DNA Binding and Cellular Uptake of Novel Ruthenium(II)-Arene Complexes Bearing Benzamide Derivatives in Human Breast Cancer Cells. Journal of Inorganic Biochemistry 2020, 210, 111155. https://doi.org/10.1016/j.jinorgbio.2020.111155. in Journal of Inorganic Biochemistry. 2020;.
https://hdl.handle.net/21.15107/rcub_cherry_4049 .

Pavlović, Marijana, Tadić, Ana, Gligorijević, Nevenka, Poljarević, Jelena, Petrović, Tamara, Dojčinović, Biljana P., Savić, Aleksandar, Radulović, Siniša, Grgurić-Šipka, Sanja, Aranđelović, Sandra, "Supplementary data for the article: Pavlović, M.; Tadić, A.; Gligorijević, N.; Poljarević, J.; Petrović, T.; Dojčinović, B.; Savić, A.; Radulović, S.; Grgurić-Šipka, S.; Aranđelović, S. Synthesis, Chemical Characterization, PARP Inhibition, DNA Binding and Cellular Uptake of Novel Ruthenium(II)-Arene Complexes Bearing Benzamide Derivatives in Human Breast Cancer Cells. Journal of Inorganic Biochemistry 2020, 210, 111155. https://doi.org/10.1016/j.jinorgbio.2020.111155" in Journal of Inorganic Biochemistry (2020),
https://hdl.handle.net/21.15107/rcub_cherry_4049 .

TY  - JOUR
AU  - Pavlović, Marijana
AU  - Nikolić, Stefan
AU  - Gligorijević, Nevenka
AU  - Dojčinović, Biljana P.
AU  - Aranđelović, Sandra
AU  - Grgurić-Šipka, Sanja
AU  - Radulović, Siniša
PY  - 2019
UR  - https://cherry.chem.bg.ac.rs/handle/123456789/2854
AB  - Three new ruthenium(II)-arene complexes with pyrido[2′,3′:5,6]pyrazino[2,3-f][1, 10]phenanthroline (ppf) of general formula: C1 ([(ƞ 6 -benzene)Ru(ppf)Cl]PF 6 , C2 ([(ƞ 6 -toluene)Ru(ppf)Cl]PF 6 ) and C3 ([(ƞ 6 -p-cymene)Ru(ppf)Cl]PF 6 ) have been synthesized. The structures of complexes were determined by elemental analysis, IR, ESI–MS, as well as with 1 H and 13 C NMR spectroscopy. Cytotoxic activity has been evaluated in three different human neoplastic cell lines (A549, A375, LS 174T) and in one human non-tumor cell line (MRC-5), by the MTT assay. Complexes C1–C3 showed IC 50 values in the micromolar range below 100 µM. Complex C3, carrying ƞ 6 -p-cymene as the arene ligand, exhibited cytoselective activity toward human malignant melanoma A375 cells (IC 50 = 15.8 ± 2.7 µM), and has been selected for further analyses of its biological effects. Drug-accumulation study performed in the A375 cells disclosed that C3 possess lower ability of entering the cells compared to cisplatin and distributes approximately equally in the cytosol and membrane/organelle fraction of cells. Investigations in the 3D model of A375 cells, disclosed different effects of the complex C3 and cisplatin on growth of multicellular tumor spheroids (MCTSs). While the size of cisplatin-treated MCTSs decreased with time, MCTSs treated with C3 continued to growth. Differences in structural organization and biological activity of this type of ruthenium(II)-arene complexes versus cisplatin in A375 malignant melanoma cells pointed out their different modes of action, and necessity for further biological studies and optimizations for potential applications.
PB  - Springer Link
T2  - Journal of Biological Inorganic Chemistry
T1  - New organoruthenium compounds with pyrido[2′,3′:5,6]pyrazino[2,3-f][1, 10]phenanthroline: synthesis, characterization, cytotoxicity, and investigation of mechanism of action
VL  - 24
IS  - 2
SP  - 297
EP  - 310
DO  - 10.1007/s00775-019-01647-4
ER  - 

@article{
author = "Pavlović, Marijana and Nikolić, Stefan and Gligorijević, Nevenka and Dojčinović, Biljana P. and Aranđelović, Sandra and Grgurić-Šipka, Sanja and Radulović, Siniša",
year = "2019",
abstract = "Three new ruthenium(II)-arene complexes with pyrido[2′,3′:5,6]pyrazino[2,3-f][1, 10]phenanthroline (ppf) of general formula: C1 ([(ƞ 6 -benzene)Ru(ppf)Cl]PF 6 , C2 ([(ƞ 6 -toluene)Ru(ppf)Cl]PF 6 ) and C3 ([(ƞ 6 -p-cymene)Ru(ppf)Cl]PF 6 ) have been synthesized. The structures of complexes were determined by elemental analysis, IR, ESI–MS, as well as with 1 H and 13 C NMR spectroscopy. Cytotoxic activity has been evaluated in three different human neoplastic cell lines (A549, A375, LS 174T) and in one human non-tumor cell line (MRC-5), by the MTT assay. Complexes C1–C3 showed IC 50 values in the micromolar range below 100 µM. Complex C3, carrying ƞ 6 -p-cymene as the arene ligand, exhibited cytoselective activity toward human malignant melanoma A375 cells (IC 50 = 15.8 ± 2.7 µM), and has been selected for further analyses of its biological effects. Drug-accumulation study performed in the A375 cells disclosed that C3 possess lower ability of entering the cells compared to cisplatin and distributes approximately equally in the cytosol and membrane/organelle fraction of cells. Investigations in the 3D model of A375 cells, disclosed different effects of the complex C3 and cisplatin on growth of multicellular tumor spheroids (MCTSs). While the size of cisplatin-treated MCTSs decreased with time, MCTSs treated with C3 continued to growth. Differences in structural organization and biological activity of this type of ruthenium(II)-arene complexes versus cisplatin in A375 malignant melanoma cells pointed out their different modes of action, and necessity for further biological studies and optimizations for potential applications.",
publisher = "Springer Link",
journal = "Journal of Biological Inorganic Chemistry",
title = "New organoruthenium compounds with pyrido[2′,3′:5,6]pyrazino[2,3-f][1, 10]phenanthroline: synthesis, characterization, cytotoxicity, and investigation of mechanism of action",
volume = "24",
number = "2",
pages = "297-310",
doi = "10.1007/s00775-019-01647-4"
}

Pavlović, M., Nikolić, S., Gligorijević, N., Dojčinović, B. P., Aranđelović, S., Grgurić-Šipka, S.,& Radulović, S.. (2019). New organoruthenium compounds with pyrido[2′,3′:5,6]pyrazino[2,3-f][1, 10]phenanthroline: synthesis, characterization, cytotoxicity, and investigation of mechanism of action. in Journal of Biological Inorganic Chemistry
Springer Link., 24(2), 297-310.
https://doi.org/10.1007/s00775-019-01647-4

Pavlović M, Nikolić S, Gligorijević N, Dojčinović BP, Aranđelović S, Grgurić-Šipka S, Radulović S. New organoruthenium compounds with pyrido[2′,3′:5,6]pyrazino[2,3-f][1, 10]phenanthroline: synthesis, characterization, cytotoxicity, and investigation of mechanism of action. in Journal of Biological Inorganic Chemistry. 2019;24(2):297-310.
doi:10.1007/s00775-019-01647-4 .

Pavlović, Marijana, Nikolić, Stefan, Gligorijević, Nevenka, Dojčinović, Biljana P., Aranđelović, Sandra, Grgurić-Šipka, Sanja, Radulović, Siniša, "New organoruthenium compounds with pyrido[2′,3′:5,6]pyrazino[2,3-f][1, 10]phenanthroline: synthesis, characterization, cytotoxicity, and investigation of mechanism of action" in Journal of Biological Inorganic Chemistry, 24, no. 2 (2019):297-310,
https://doi.org/10.1007/s00775-019-01647-4 . .

TY  - JOUR
AU  - Pavlović, Marijana
AU  - Dimitrijevic, A.
AU  - Trbojević-Ivić, Jovana
AU  - Milosavic, N.
AU  - Gavrović-Jankulović, Marija
AU  - Bezbradica, Dejan
AU  - Velickovic, D.
PY  - 2013
UR  - https://cherry.chem.bg.ac.rs/handle/123456789/1432
AB  - alpha-1,4-Glucosidase from Saccharomyces cerevisiae is an enzyme which is widely used in synthesis of different drugs. Glucosidase inhibitors are studied as potential drugs for prevention of HIV and diabetes. For understanding of these processes it is very important to have insights in the transglucosylation activity of this enzyme. In this paper the kinetics of transglucosylation reaction catalyzed by this enzyme in the synthesis of benzyl alcohol glucoside was studied and all relevant kinetic constants for this system are found. It was shown one additional property of transglycosylation reactions catalyzed by glycosidases-inhibition by both, glucose acceptor and glucose donor, and mechanisms for these inhibitions were proposed.
PB  - Maik Nauka/Interperiodica/Springer, New York
T2  - Russian Journal of Physical Chemistry A
T1  - A study of transglucosylation kinetic in an enzymatic synthesis of benzyl alcohol glucoside by alpha-glucosidase from S-cerevisiae
VL  - 87
IS  - 13
SP  - 2285
EP  - 2288
DO  - 10.1134/S0036024413130207
ER  - 

@article{
author = "Pavlović, Marijana and Dimitrijevic, A. and Trbojević-Ivić, Jovana and Milosavic, N. and Gavrović-Jankulović, Marija and Bezbradica, Dejan and Velickovic, D.",
year = "2013",
abstract = "alpha-1,4-Glucosidase from Saccharomyces cerevisiae is an enzyme which is widely used in synthesis of different drugs. Glucosidase inhibitors are studied as potential drugs for prevention of HIV and diabetes. For understanding of these processes it is very important to have insights in the transglucosylation activity of this enzyme. In this paper the kinetics of transglucosylation reaction catalyzed by this enzyme in the synthesis of benzyl alcohol glucoside was studied and all relevant kinetic constants for this system are found. It was shown one additional property of transglycosylation reactions catalyzed by glycosidases-inhibition by both, glucose acceptor and glucose donor, and mechanisms for these inhibitions were proposed.",
publisher = "Maik Nauka/Interperiodica/Springer, New York",
journal = "Russian Journal of Physical Chemistry A",
title = "A study of transglucosylation kinetic in an enzymatic synthesis of benzyl alcohol glucoside by alpha-glucosidase from S-cerevisiae",
volume = "87",
number = "13",
pages = "2285-2288",
doi = "10.1134/S0036024413130207"
}

Pavlović, M., Dimitrijevic, A., Trbojević-Ivić, J., Milosavic, N., Gavrović-Jankulović, M., Bezbradica, D.,& Velickovic, D.. (2013). A study of transglucosylation kinetic in an enzymatic synthesis of benzyl alcohol glucoside by alpha-glucosidase from S-cerevisiae. in Russian Journal of Physical Chemistry A
Maik Nauka/Interperiodica/Springer, New York., 87(13), 2285-2288.
https://doi.org/10.1134/S0036024413130207

Pavlović M, Dimitrijevic A, Trbojević-Ivić J, Milosavic N, Gavrović-Jankulović M, Bezbradica D, Velickovic D. A study of transglucosylation kinetic in an enzymatic synthesis of benzyl alcohol glucoside by alpha-glucosidase from S-cerevisiae. in Russian Journal of Physical Chemistry A. 2013;87(13):2285-2288.
doi:10.1134/S0036024413130207 .

Pavlović, Marijana, Dimitrijevic, A., Trbojević-Ivić, Jovana, Milosavic, N., Gavrović-Jankulović, Marija, Bezbradica, Dejan, Velickovic, D., "A study of transglucosylation kinetic in an enzymatic synthesis of benzyl alcohol glucoside by alpha-glucosidase from S-cerevisiae" in Russian Journal of Physical Chemistry A, 87, no. 13 (2013):2285-2288,
https://doi.org/10.1134/S0036024413130207 . .